GitHub’s Octoverse 2025 report reveals a "convenience loop" where AI coding assistants drive language choice. TypeScript’s 66% surge to the #1 spot highlights a shift toward static typing, as types ...

Biological systems are notoriously tough to model, especially when it comes to figuring out the axons, neurons, blood vessels, and other structural components of gray matter, or the tissue that makes ...

WASHINGTON — Array Labs, a Silicon Valley startup developing radar-based Earth observation satellites, announced Jan. 5 it raised $20 million in a Series A round as it pushes to bring lower-cost ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...

Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune misled investors about the prospects of its IGNYTE trial for RP1 (vusolimogene ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

LOS ANGELES, Sept. 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" ...

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune ...